Review Article
Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females
Table 8
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population is according to protocol, which included females seronegative to HPV 16/18 at baseline who received all three doses of study vaccine or placebo according to schedule, complied with the blood sampling schedule, and did not become positive for HPV-16/18-DNA during the trial. Seropositivity at 48 months among women seronegative for HPV 16/18 at baseline, who received Cervarix in the ATP cohort. Seropositivity is defined as antibody titers ≥8 ELU/mL for HPV 16; ≥7 ELU/mL for HPV-18. Measured by type-specific ELISA testing. |